Evidence map›Paper›PMID 35870446›Full record

ArticleMed (New York, N.Y.)2022

Acute HIV-1 infection viremia associate with rebound upon treatment interruption.

Thembi Mdluli, Yifan Li, Suteeraporn Pinyakorn, Daniel B Reeves, E Fabian Cardozo-Ojeda, Adam Yates, Jintana Intasan, Somporn Tipsuk, Nittaya Phanuphak, Carlo Sacdalan and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Med (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Unique CD8bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Early immune responses anticipate HIV rebound and precede viral control.bioRxiv : the preprint server for biology · 2026
    Article
  5. Maintenance of intestinal CX3CR1Nature communications · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Activation of CXCR3Journal of virology · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Thembi MdluliUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Yifan LiUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Suteeraporn PinyakornUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Daniel B ReevesVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
E Fabian Cardozo-OjedaVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Adam YatesUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Jintana IntasanSEARCH, Institute of HIV Research and Innovation, Bangkok 10330, Thailand.
Somporn TipsukSEARCH, Institute of HIV Research and Innovation, Bangkok 10330, Thailand.
Nittaya PhanuphakSEARCH, Institute of HIV Research and Innovation, Bangkok 10330, Thailand.
Carlo SacdalanSEARCH, Institute of HIV Research and Innovation, Bangkok 10330, Thailand.
Donn J ColbyUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA; SEARCH, Institute of HIV Research and Innovation, Bangkok 10330, Thailand.
Eugène KroonSEARCH, Institute of HIV Research and Innovation, Bangkok 10330, Thailand.
Trevor A CrowellUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Rasmi ThomasUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Merlin L RobbUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Jintanat AnanworanichDepartment of Global Health, Amsterdam Medical Center, University of Amsterdam, Amsterdam, 1105 BP, the Netherlands.
Mark de SouzaHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA; SEARCH, Institute of HIV Research and Innovation, Bangkok 10330, Thailand.
Praphan PhanuphakSEARCH, Institute of HIV Research and Innovation, Bangkok 10330, Thailand.
Daniel J StiehJanssen Vaccines & Prevention BV, Leiden, 2333 CN, the Netherlands.
Frank L TomakaJanssen Vaccines & Prevention BV, Leiden, 2333 CN, the Netherlands.
Lydie TrautmannVaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, OR 97006, USA.
Julie A AkeUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Denise C HsuUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Leilani V FranciscoUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Sandhya VasanUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
Morgane RollandUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA. Electronic address: mrolland@hivresearch.org.

Funding

SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
Combined Immunologic Approaches to Cure HIV-1UM1AI126603 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., MELLORS, JOHN W · 2016 to 2020
$23.6M
Simulating persistence and elimination of the HIV reservoirK25AI155224 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI REEVES, DANIEL · 2020 to 2024
$581k
NIAID NIH HHS K25 AI155224NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI126603
6 · The paper itself

Abstract

backgroundAnalytic treatment interruption (ATI) studies evaluate strategies to potentially induce remission in people living with HIV-1 but are often limited in sample size. We combined data from four studies that tested three interventions (vorinostat/hydroxychloroquine/maraviroc before ATI, Ad26/MVA vaccination before ATI, and VRC01 antibody infusion during ATI).

methodsThe statistical validity of combining data from these participants was evaluated. Eleven variables, including HIV-1 viral load at diagnosis, Fiebig stage, and CD4

findingsParticipants had homogeneous demographic and clinical characteristics. Because an antiviral effect was seen in participants who received VRC01 infusion post-ATI, these participants were excluded from the analysis, permitting a pooled analysis of 53 participants. Time to viral rebound was significantly associated with variables measured at the beginning of infection: pre-antiretroviral therapy (ART) viral load (HR = 1.34, p = 0.022), time to viral suppression post-ART initiation (HR = 1.07, p < 0.001), and area under the viral load curve (HR = 1.34, p = 0.026).

conclusionsWe show that higher viral loads in acute HIV-1 infection were associated with faster viral rebound, demonstrating that the initial stage of HIV-1 infection before ART initiation has a strong impact on viral rebound post-ATI years later.

fundingThis work was supported by a cooperative agreement between the Henry M. Jackson Foundation for the Advancement of Military Medicine and the US Department of the Army (W81XWH-18-2-0040). This research was funded, in part, by the US National Institute of Allergy and Infectious Diseases (AAI20052001) and the I4C Martin Delaney Collaboratory (5UM1AI126603-05).

Indexed as

HIV-1HIV InfectionsAnti-Retroviral AgentsHumansViral LoadViremiaAnti-Retroviral Agentsanalytic treatment interruptioncorrelates of HIV-1 reboundHIV-1 acute infectionHIV-1 cureTranslation to patients

Identifiers

PMID35870446
PMCPMC9464709

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.